Literature DB >> 25283184

Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.

David N Burns1, Cynthia Grossman, Jim Turpin, Vanessa Elharrar, Fulvia Veronese.   

Abstract

Treatment as prevention is expected to have a major role in reducing HIV incidence, but other prevention interventions will also be required to bring the epidemic under control, particularly among key populations. One or more forms of pre-exposure prophylaxis (PrEP) will likely play a critical role. Oral PrEP with emtricitabine-tenofovir (Truvada®) is currently available in the US and some other countries, but uptake has been slow. We review the concerns that have contributed to this slow uptake and discuss current and future research in this critical area of HIV prevention research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25283184     DOI： 10.1007/s11904-014-0234-8

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN： 1548-3568            Impact factor:   5.071


  71 in total

1.  The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.

Authors:  Rochelle P Walensky; Ji-Eun Park; Robin Wood; Kenneth A Freedberg; Callie A Scott; Linda-Gail Bekker; Elena Losina; Kenneth H Mayer; George R Seage; A David Paltiel
Journal:  Clin Infect Dis       Date:  2012-04-03       Impact factor: 9.079

2.  Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.

Authors:  Ayman Akil; Michael A Parniak; Charlene S Dezzuitti; Bernard J Moncla; Marilyn R Cost; Mingguang Li; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2011-06-01       Impact factor: 4.617

Review 3.  Treatment as prevention: translating efficacy trial results to population effectiveness.

Authors:  Geoffrey P Garnett; Stephen Becker; Stefano Bertozzi
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

Review 4.  Use of antiretrovirals for HIV prevention: what do we know and what don't we know?

Authors:  Jared M Baeten; Robert Grant
Journal:  Curr HIV/AIDS Rep       Date:  2013-06       Impact factor: 5.071

5.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.

Authors:  Amarendra Pegu; Zhi-yong Yang; Jeffrey C Boyington; Lan Wu; Sung-Youl Ko; Stephen D Schmidt; Krisha McKee; Wing-Pui Kong; Wei Shi; Xuejun Chen; John-Paul Todd; Norman L Letvin; Jinghe Huang; Martha C Nason; James A Hoxie; Peter D Kwong; Mark Connors; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

6.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

7.  Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.

Authors:  Michael Martin; Suphak Vanichseni; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Roman J Gvetadze; Marcel E Curlin; Manoj Leethochawalit; Sithisat Chiamwongpaet; Thitima Cherdtrakulkiat; Rapeepan Anekvorapong; Wanna Leelawiwat; Nartlada Chantharojwong; Janet M McNicholl; Lynn A Paxton; Somyot Kittimunkong; Kachit Choopanya
Journal:  Clin Infect Dis       Date:  2014-05-14       Impact factor: 9.079

8.  HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.

Authors:  A David Paltiel; Kenneth A Freedberg; Callie A Scott; Bruce R Schackman; Elena Losina; Bingxia Wang; George R Seage; Caroline E Sloan; Paul E Sax; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2009-03-15       Impact factor: 9.079

9.  Global expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxis.

Authors:  Manjula Gunawardana; Madeline Mullen; John A Moss; Richard B Pyles; Rebecca J Nusbaum; Jignesh Patel; Kathleen L Vincent; Charles Wang; Chao Guo; Yate-Ching Yuan; Charles D Warden; Marc M Baum
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

10.  Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).

Authors:  Albert Y Liu; Qiyun Yang; Yong Huang; Peter Bacchetti; Peter L Anderson; Chengshi Jin; Kathy Goggin; Kristefer Stojanovski; Robert Grant; Susan P Buchbinder; Ruth M Greenblatt; Monica Gandhi
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240
View more
  14 in total

1.  Potential Healthcare Insurance and Provider Barriers to Pre-Exposure Prophylaxis Utilization Among Young Men Who Have Sex with Men.

Authors:  Sarah J Marks; Roland C Merchant; Melissa A Clark; Tao Liu; Joshua G Rosenberger; Jose Bauermeister; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2017-11       Impact factor: 5.078

Review 2.  Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities.

Authors:  Kathrine Meyers; Sarit A Golub
Journal:  Curr Opin HIV AIDS       Date:  2015-07       Impact factor: 4.283

3.  A Promising PrEP Navigation Intervention for Transgender Women and Men Who Have Sex with Men Experiencing Multiple Syndemic Health Disparities.

Authors:  Cathy J Reback; Kirsty A Clark; Dennis Rünger; Anne E Fehrenbacher
Journal:  J Community Health       Date:  2019-12

4.  Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.

Authors:  Milena Veselinovic; Kuo-Hsiung Yang; Craig Sykes; Leila Remling-Mulder; Angela D M Kashuba; Ramesh Akkina
Journal:  Virology       Date:  2016-01-06       Impact factor: 3.616

5.  Belief in Treatment as Prevention and Its Relationship to HIV Status and Behavioral Risk.

Authors:  Kiffer G Card; Heather L Armstrong; Nathan J Lachowsky; Zishan Cui; Paul Sereda; Allison Carter; Julio S G Montaner; Robert S Hogg; Eric A Roth; David M Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2018-01-01       Impact factor: 3.731

6.  Sexual Identity Disclosure and Awareness of HIV Prevention Methods Among Black Men Who Have Sex With Men.

Authors:  Ryan J Watson; Jessica N Fish; Aerielle Allen; Lisa Eaton
Journal:  J Sex Res       Date:  2017-10-12

7.  Depression and HIV Transmission Risk among Methamphetamine-Using Men who have Sex with Men.

Authors:  Jesse B Fletcher; Kirsty A Clark; Cathy J Reback
Journal:  Addict Res Theory       Date:  2020-08-25

8.  Examining the Potential of Pre-exposure Prophylaxis (PrEP) for HIV Prevention in a Community Sample of Persons Who Use Stimulants Living in the Southern United States.

Authors:  Sheri L Towe; Catherine A Sullivan; Mehri S McKellar; Christina S Meade
Journal:  AIDS Behav       Date:  2021-05

9.  Pre-exposure prophylaxis use among HIV serodiscordant couples: a qualitative study in Mozambique.

Authors:  Daniel E Sack; Caroline De Schacht; Paula Paulo; Erin Graves; Almiro M Emílio; Ariano Matino; Carlota L Fonseca; Arifo U Aboobacar; Sara Van Rompaey; Carolyn M Audet
Journal:  Glob Health Action       Date:  2021-01-01       Impact factor: 2.640

10.  Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis.

Authors:  Kimberly A Koester; Robert M Grant
Journal:  Clin Infect Dis       Date:  2015-09-01       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.